Erste Group Bank Forecasts Increased Earnings for AbbVie

AbbVie Inc. (NYSE:ABBV) – Investment analysts at Erste Group Bank lifted their FY2027 earnings per share (EPS) estimates for shares of AbbVie in a report released on Thursday, October 8th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $16.34 for the year, up from their previous estimate of $16.19. Erste Group Bank has a “Buy” rating on the stock. The consensus estimate for AbbVie’s current full-year earnings is $13.95 per share.

Other research analysts have also recently issued reports about the company. Argus lifted their price target on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. BMO Capital Markets upped their price objective on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Canaccord Genuity Group raised their price objective on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Scotiabank lifted their target price on shares of AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $277.18.

AbbVie Stock Down 2.2%

AbbVie stock opened at $274.82 on Wednesday. The firm has a market cap of $485.55 billion, a price-to-earnings ratio of 77.63, a price-to-earnings-growth ratio of 1.28 and a beta of 0.24. AbbVie has a 52 week low of $190.75 and a 52 week high of $283.43. The business’s 50-day moving average price is $260.41 and its 200 day moving average price is $237.87.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AbbVie

A number of large investors have recently bought and sold shares of ABBV. First Citizens Bank & Trust Co. raised its holdings in AbbVie by 25.4% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 54,546 shares of the company’s stock worth $14,269,000 after purchasing an additional 11,032 shares during the period. Fearless Solutions LLC dba Best Invest boosted its position in AbbVie by 0.4% during the third quarter. Fearless Solutions LLC dba Best Invest now owns 12,615 shares of the company’s stock worth $3,300,000 after purchasing an additional 47 shares in the last quarter. ASK Capital Investment Managers LLC acquired a new stake in AbbVie in the third quarter valued at approximately $5,703,000. XY Planning Network Inc. grew its holdings in AbbVie by 33.4% in the third quarter. XY Planning Network Inc. now owns 1,846 shares of the company’s stock valued at $483,000 after purchasing an additional 462 shares during the period. Finally, Define Financial LLC acquired a new stake in AbbVie in the third quarter valued at approximately $237,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Potential Q3 revenue beat: RBC expects AbbVie to exceed third-quarter revenue estimates, driven by continued momentum for immunology drugs Skyrizi and Rinvoq, as well as psychiatric medicine Vraylar. This supports expectations that newer products can offset Humira’s loss of exclusivity. AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says
• Positive Sentiment: Encouraging Skyrizi data: New Phase 3 AFFIRM results showed favorable clinical and endoscopic outcomes for subcutaneous Skyrizi in patients with moderately to severely active Crohn’s disease. The data could strengthen Skyrizi’s position in a major growth market and expand AbbVie’s immunology opportunity. AbbVie Presents New Phase 3 AFFIRM Data
• Positive Sentiment: Pipeline and analyst support: Recent Crohn’s disease data for Skyrizi and Rinvoq, cancer-related regulatory milestones for Temab-A, and early metabolic-treatment data are improving the outlook for AbbVie’s post-Humira growth. RBC reaffirmed its “Outperform” rating, although its target implies only limited additional upside. AbbVie Could Be 44% Below Fair Value on Fresh Pipeline Wins
• Neutral Sentiment: Strategic expansion: AbbVie’s acquisition of Apogee and related leadership moves highlight the company’s effort to replenish its pipeline through business development, but the long-term financial impact remains uncertain. Biotech Builder Paragon Imports Apogee’s Top Brass After AbbVie Buyout
• Negative Sentiment: Valuation and execution risks: At a high earnings multiple near its recent peak, ABBV may be vulnerable to profit-taking even with positive clinical news. Investors also remain concerned about Humira’s ongoing sales erosion, increasing immunology competition, and whether Skyrizi and Rinvoq can sustain their rapid growth.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.